Home > Insider Trading > Filing (0000919574-24-004878)

Filing Details

Accession Number:: 0000919574-24-004878
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-08-26 20:10:10
Reporting Period:: 2024-08-22

Accepted Time:: 2024-08-26 20:10:10
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1162194	Standard Biotools Inc.	LAB	Laboratory Analytical Instruments (3826)	770513190

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1534260	Casdin Partners Gp, Llc	1350 Avenue Of The Americas Suite 2600 New York NY 10019	Yes	No	Yes	No
1534261	Casdin Capital, Llc	1350 Avenue Of The Americas Suite 2600 New York NY 10019	Yes	No	Yes	No
1534264	Eli Casdin	1350 Avenue Of The Americas Suite 2600 New York NY 10019	Yes	No	Yes	No
1534265	Casdin Partners Master Fund, L.p.	1350 Avenue Of The Americas Suite 2600 New York NY 10019	Yes	No	Yes	No
1823061	Casdin Private Growth Equity Fund, L.p.	1350 Avenue Of The Americas Suite 2600 New York NY 10019	Yes	No	No	No
1864554	Casdin Private Growth Equity Fund Gp, Llc	1350 Avenue Of The Americas Suite 2600 New York NY 10019	Yes	No	No	No
1891102	Casdin Private Growth Equity Fund Ii, L.p.	1350 Avenue Of The Americas Suite 2600 New York NY 10019	Yes	No	No	No
1919480	Casdin Private Growth Equity Fund Ii Gp, Llc	1350 Avenue Of The Americas, Suite 2600 New York NY 10019	Yes	No	No	No
2028254	Casdin Amplify Fund, Lp	1350 Avenue Of The Americas Suite 2600 New York NY 10019	Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-08-22	307,900	$1.96	53,333,721	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2024-08-23	292,100	$2.13	53,625,821	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2024-08-26	150,000	$2.15	53,775,821	No	4	P	Indirect	See footnotet

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnotet

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	545,000	Indirect	See footnote
Common Stock	13,939,637	Indirect	See footnote
Common Stock	2,781,432	Direct
Common Stock	2,744,219	Indirect	See footnote

Footnotes

The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.9464 to $1.9587. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.
The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.115 to $2.1505. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.1223 to $2.1719. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
The securities are owned directly by Casdin Amplify Fund, LP ("Amplify") and are deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
Includes Restricted Stock United ("RSUs"). Certain RSUs vest in full on the earlier to occur of June 28, 2025 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date and other RSUs vested as to 25% on July 23, 2024 and thereafter in two equal installments on the 15th day of the last month of each remaining fiscal quarter of 2024, subject to the Reporting Person's continued service through the applicable vesting date.
The securities are owned directly by Eli Casdin.
The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.